Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102874 | 0.88 | GRM5 (0.55) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4230162 | 0.87 | GRM5 (0.40) | GRM5DRD2DRD3KCNH2 | |
| SCHEMBL4107167 | 0.86 | GRM5 (0.54) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2897662 | 0.83 | GRM5 (0.55) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2897665 | 0.83 | GRM5 (0.55) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4106727 | 0.82 | NPC1 (0.41) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4106857 | 0.82 | GRM5 (0.36) | GRM5NPC1RAB9AMAPT | |
| SCHEMBL4097151 | 0.82 | GRM5 (0.54) | GRM5NPC1RAB9A | |
| SCHEMBL13871103 | 0.79 | GRM5 (0.44) | GRM5NPC1RAB9ADRD2DRD3 | |
| SCHEMBL4107029 | 0.79 | GRM5 (0.44) | GRM5NPC1RAB9ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| WO-2009054791-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885SMN1; SMN2 2221/4885NPC1 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.